Drug intelligence / Profile preview

EPAX 6000 TG

Development stage
Phase 1
Lead developer
Epax
Modality
Small Molecules
Administration
Oral
01

Overview

EPAX 6000 TG is a concentrated marine-derived omega-3 fatty acid supplement in triglyceride form, primarily composed of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is manufactured by Epax Norway AS. In clinical research, particularly studies led by the Medical University of Vienna, it is being investigated for its potential to modulate dopamine-dependent cognitive functions and neuroplasticity in patients with schizophrenia and individuals at high risk for psychosis. The mechanism involves the incorporation of long-chain polyunsaturated fatty acids (PUFAs) into neuronal membranes, influencing membrane fluidity, signal transduction, and neuroinflammation. It also acts as a ligand for various nuclear and membrane-bound receptors that regulate metabolic and inflammatory pathways.

Brand names
EPAX 6000 TGEPAX6000 TGEPAX-6000 TG
Other names
omega-3 fatty acidsomega3 fatty acidsomega 3 fatty acidsfish oil concentrateEPAX 6000EPAX6000EPAX-6000
02

Targets

FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on EPAX 6000 TG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPAX 6000 TG.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call